Photo: یحیی بیابادی / Wikimedia Commons, CC BY 4.0. File image, not from the event described.

Health News

IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer

By Dare OnlineHustle Health, 6 October 2026, 2 min read

IceCure has expanded its ProSense ChoICE study for low-risk breast cancer by adding Legacy Health in Portland, OR, as a U.S. clinical site.

According to reports published by PR Newswire, IceCure has expanded its ProSense ChoICE study for low-risk breast cancer by adding Legacy Health in Portland, Oregon, as a United States clinical site.

What the research found

According to the PR Newswire reports, the clinical study focuses on the ProSense system and targets low-risk breast cancer. The recent expansion brings Legacy Health in Portland, Oregon, on board as an active U.S. clinical site participating in the research.

What this means for you

Clinical study expansions often provide broader geographical access for ongoing research initiatives within healthcare settings. Medical researchers and institutional review boards generally oversee these multi-site studies to gather data on medical devices and procedures.

Readers who have personal health concerns or questions regarding clinical studies and medical treatments should speak with a qualified healthcare professional.

Health disclaimer: This article is for general information only and is not medical advice. It does not replace diagnosis, treatment, or guidance from a licensed doctor or healthcare provider. Always consult a qualified professional about your own health or before changing any medication or treatment.

Where this comes from. Compiled from published reports, including PR Newswire. We rewrite in our own words and update when new details are confirmed.

Health news, every day
Studies, wellness tips and public health updates from Nigeria and the world.
Read more on Dare OnlineHustle